Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment.

ABSTRACT:

Objective

Anlotinib hydrochloride is a multitarget tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor, c-Kit, and c-MET; therefore, it exhibits both antitumor and anti-angiogenetic activities. A phase III trial has shown that anlotinib improved progression-free survival (PFS) and overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC), who presented with progressive disease or intolerance after standard chemotherapy. This study aimed to analyze the characteristics of patients receiving anlotinib treatment to determine the dominant populations who are fit for the treatment.

Methods

Data were collected from March 2015 to January 2017 from a ran

SUBMITTER: Wang J 

PROVIDER: S-EPMC6372914 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature